查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1666168

全球乳房影像市場 - 2025 至 2033 年

Global Breast Imaging Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024 年全球乳房影像市場規模達到 47.4 億美元，預計到 2033 年將達到 97.7 億美元，2025-2033 年預測期內的複合年成長率為 8.43%。

乳房影像涵蓋多種診斷技術，旨在觀察和評估乳房組織以識別腫塊、囊腫或乳癌跡像等異常情況。這些方法對於早期發現、診斷和監測乳房疾病至關重要，有助於及時有效地採取治療干預措施。

市場動態：

促進因素與約束因素

科技進步日新月異

乳房影像技術的進步透過提高診斷準確性、改善患者治療效果和增加可近性，極大地推動了市場成長。數位乳房 X 光攝影、3D 斷層合成和人工智慧增強成像等技術能夠實現更早、更精確的檢測，即使在緻密的乳房組織中也是如此，同時最大限度地減少假陽性。例如，2024 年 8 月，OSF HealthCare 在其秘魯聖伊麗莎白醫療中心推出了 Invenia ABUS 2.0（自動乳房超音波系統），標誌著乳癌篩檢領域的重大技術進步。 Invenia ABUS 2.0 專門用於檢測因乳房組織密度而可能隱藏在乳房 X 光檢查照片中的癌症，在乳房 X 光檢查照片中，緻密組織和癌變腫塊均呈現白色。

同樣，2022年6月，Seno Medical的Imagio乳房影像系統獲得了美國食品藥物管理局（FDA）設備和放射健康中心（CDRH）的補充上市前批准（PMA）。 Seno Medical 的 Imagio 乳房成像系統代表了乳房成像領域的重大技術進步，該創新系統利用光聲 (OA) 和超音波 (US) 技術的組合來提供有關乳房病變的即時資訊。

此外，隨著醫療保健提供者和患者認知到早期和準確診斷的重要性，對先進解決方案的需求正在激增。隨著技術的進步，全球範圍內獲取高品質成像的機會正在改善，包括服務不足的地區。對新影像模式和人工智慧應用的持續研究進一步推動了市場成長，確保更多女性能夠從早期檢測計劃中受益，並促進乳癌檢測和治療的持續進步。

乳房成像系統成本高昂

與乳房成像系統相關的高成本對市場的成長構成了重大挑戰。例如，數位乳房 X 光攝影系統的價格範圍從 65,000 美元到 95,000 美元不等，具體取決於型號和製造商。購買和維護數位乳房 X 光攝影機、MRI 系統和 3D 斷層合成設備等設備需要大量的前期投資，這可能會給醫院、診所和醫療保健提供者帶來沉重的財務負擔。

目錄

第 1 章：方法與範圍

第 2 章：定義與概述

第 3 章：執行摘要

第 4 章：動態

  • 影響因素
    • 驅動程式
      • 科技進步日新月異
    • 限制
      • 乳房成像系統成本高昂
    • 機會
  • 影響分析

第5章：戰略洞察與產業展望

  • 市場領導者和先驅者
    • 新興先鋒和傑出參與者
    • 擁有最大銷售品牌的成熟領導者
    • 擁有成熟產品的市場領導者
  • CXO 觀點
  • 最新進展與突破
  • 案例研究/正在進行的研究
  • 監管和報銷情況
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 波特五力分析
  • 供應鏈分析
  • 專利分析
  • SWOT 分析
  • 未滿足的需求和差距
  • 市場進入和擴張的推薦策略
  • 情境分析：最佳情況、基本情況和最壞情況預測
  • 定價分析和價格動態
  • 關鍵意見領袖

第 6 章：按類型

  • 乳房X光檢查
  • 診斷性乳房X光檢查
  • 乳房斷層合成
  • 乳房超音波檢查
  • 乳房 MRI

第 7 章：按技術

  • 電腦斷層掃描 (CT)
  • 磁振造影（MRI）掃描
  • 超音波
  • 正子斷層掃描 (PET)
  • 其他

第 8 章：按應用

  • 乳房疾病
  • 乳癌
  • 良性腫瘤
  • 囊腫
  • 其他

第 9 章：按最終用戶

  • 醫院
  • 診斷中心
  • 研究機構
  • 其他

第 10 章：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲

第 11 章：競爭格局

  • 競爭格局
  • 市場定位/佔有率分析
  • 併購分析

第 12 章：公司簡介

  • GE HealthCare
    • 公司概況
    • 產品組合
      • 產品描述
      • 產品關鍵績效指標 (KPI)
      • 歷史和預測產品銷售量
      • 產品銷售量
    • 財務概覽
      • 公司收入
      • 地區收入佔有率
      • 收入預測
    • 主要進展
      • 合併與收購
      • 關鍵產品開發活動
      • 監管部門批准等
    • SWOT 分析
  • Koning Health
  • FUJIFILM Holdings Corporation
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • Hologic, Inc.
  • Siemens Healthineers AG
  • Agfa-Gevaert Group.
  • Koninklijke Philips NV
  • Planmed Oy
  • Seno Medical
  • Similar data will be provided for each market player.

第 13 章：附錄

簡介目錄
Product Code: MI878

The global breast imaging market reached US$ 4.74 billion in 2024 and is expected to reach US$ 9.77 billion by 2033, growing at a CAGR of 8.43% during the forecast period 2025-2033.

Breast imaging encompasses a variety of diagnostic techniques aimed at visualizing and evaluating breast tissue to identify abnormalities such as lumps, cysts, or signs of breast cancer. These methods are essential for early detection, diagnosis, and monitoring of breast conditions, thereby facilitating timely and effective treatment interventions.

Market Dynamics: Drivers & Restraints

Rising technological advancements

Advancements in breast imaging technologies are significantly propelling market growth by enhancing diagnostic accuracy, improving patient outcomes, and increasing accessibility. Technologies like digital mammography, 3D tomosynthesis, and AI-enhanced imaging enable earlier and more precise detection, even in dense breast tissue, while minimizing false positives. For instance, in August 2024, OSF HealthCare introduced the Invenia ABUS 2.0 (Automated Breast Ultrasound System) at its Saint Elizabeth Medical Center in Peru, marking a significant technological advancement in breast cancer screening. The Invenia ABUS 2.0 is specifically designed to detect cancers that may be hidden on mammograms due to the density of breast tissue, where both dense tissue and cancerous masses appear white.

Similarly, in June 2022, Seno Medical's Imagio Breast Imaging System received supplemental premarket approval (PMA) from the Center for Devices and Radiological Health (CDRH) of the US Food & Drug Administration (FDA). The Imagio Breast Imaging System by Seno Medical represents a significant technological advancement in breast imagingThis innovative system utilizes a combination of opto-acoustic (OA) and ultrasound (US) technologies to provide real-time information about breast lesions.

Additionally, the demand for advanced solutions is surging as healthcare providers and patients recognize the importance of early and accurate diagnosis. As technology progresses, access to high-quality imaging is improving globally, including in underserved regions. Continuous research into new imaging modalities and AI applications further propels market growth, ensuring more women can benefit from early detection initiatives and fostering ongoing advancements in breast cancer detection and treatment.

High costs associated with breast imaging systems

The high costs associated with breast imaging systems present a significant challenge to the growth of the market. For instance, digital mammography systems can range from $65,000 to $95,000, depending on the model and manufacturer. The high upfront investment required for purchasing and maintaining equipment such as digital mammography machines, MRI systems, and 3D tomosynthesis devices can be a significant financial burden for hospitals, clinics, and healthcare providers.

Segment Analysis

The global Breast Imaging market is segmented based on technology, end-user, and region.

Technology:

Magnetic resonance imaging (MRI) segment is expected to dominate the global Breast Imaging market share

The Magnetic Resonance Imaging (MRI) segment dominates the breast imaging market due to its advanced imaging capabilities and non-invasive nature. Innovations such as 3D MRI and contrast-enhanced MRI significantly enhance the effectiveness of breast cancer detection, particularly for women with dense breast tissue or those at high risk. For instance, in October 2022, Intermountain Healthcare is launching an abbreviated MRI screening tool specifically designed for women at higher risk of developing breast cancer. This development marks a significant advancement in the MRI segment of breast imaging, as it offers a targeted approach to enhance early detection in populations that may not benefit as much from traditional mammography. These advancements allow healthcare providers to deliver more accurate and detailed diagnostic options, leading to improved patient outcomes. The high sensitivity and specificity of MRI are crucial for early detection and effective management of breast cancer, making it a preferred choice in clinical settings.

The increasing prevalence of breast cancer drives the adoption of MRI in breast imaging. According to the World Health Organization report, In 2022, there were 2.3 million women diagnosed with breast cancer. The incidence is expected to increase which is increasing the urgent need for advanced imaging technologies like MRI. As healthcare systems emphasize early detection and preventive care, the demand for MRI continues to rise, positioning it as a leading segment in the breast imaging market. The combination of technological advancements and growing awareness about breast cancer screening underscores MRI's pivotal role in enhancing diagnostic capabilities and improving patient care.

Geographical Analysis

North America is expected to hold a significant position in the global breast imaging market share

North America is expected to hold a significant position in the global breast imaging market due to several key factors. Advancements in medical technology, particularly in imaging techniques like 3D mammography, ultrasound, and MRI, are crucial factors in maintaining North America's dominant position in the breast imaging market. As these technologies evolve, healthcare providers in the region can offer more precise, non-invasive, and effective diagnostic options.

The region's continued development of cutting-edge technologies helps solidify its leadership in the global breast imaging market, ensuring that healthcare providers have access to the latest tools for early detection and improved treatment. For instance, Seno Medical Instruments officially launched the commercially available Imagio Breast Imaging System at RSNA in November 2022, marking a significant development for breast cancer diagnostics in North America. This innovative system utilizes a combination of optoacoustic and ultrasound technology to provide real-time information about breast lesions, enabling radiologists to differentiate between benign and malignant masses more effectively.

Key market players are driving the growth of the breast imaging market in North America by focusing on technological advancements, strategic partnerships, and expanding their product portfolios. For instance, in December 2024, QT Imaging Holdings, Inc. announced the expansion of its Breast Acoustic CT Scanner to the Couri Center for Gynecology and Integrative Women's Health in Peoria, IL. This strategic initiative, executed in partnership with NXC Imaging, Inc., enhances access to innovative breast imaging technology that prioritizes patient comfort and safety while delivering high-quality diagnostic capabilities. The rising demand for breast imaging in both diagnostic and treatment applications has created significant growth opportunities for manufacturers in North America. Thus, the above factors are expected to hold the region in the dominant position.

Competitive Landscape

The major global players in the Breast Imaging market include Bayer AG, Pfizer, Inc., AbbVie, Inc, AstraZeneca, Gedeon Richter Plc., TORRENT PHARMACEUTICALS LTD., Sanofi SA, Gynogen, and Weefsel Pharma among others.

Key Developments

  • In August 2024, Izotropic Corporation announced that it is pursuing a regulatory strategy in the U.S. and EU to launch IzoView as a diagnostic device indicated for use in patients with dense breast tissue.
  • In June 2023, Koning Corporation launched adjunctive artificial intelligence (AI) software that can produce 3D CT breast images through seamless integration with the company's existing breast CT devices.
  • In January 2023, Izotropic Corporation announced that IzoView will be featured on an upcoming segment of Advancements with Ted Danson ("Advancements") via Amazon Prime Video and Bloomberg TV.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Breast Imaging Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Technology
  • 3.3. Snippet by Application
  • 3.4. Snippet by End-User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising technological advancements
    • 4.1.2. Restraints
      • 4.1.2.1. High costs associated with breast imaging systems
    • 4.1.3. Opportunity
  • 4.2. Impact Analysis

5. Strategic Insights and Industry Outlook

  • 5.1. Market Leaders and Pioneers
    • 5.1.1. Emerging Pioneers and Prominent Players
    • 5.1.2. Established leaders with largest selling Brand
    • 5.1.3. Market leaders with established Product
  • 5.2. CXO Perspectives
  • 5.3. Latest Developments and Breakthroughs
  • 5.4. Case Studies/Ongoing Research
  • 5.5. Regulatory and Reimbursement Landscape
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa
  • 5.6. Porter's Five Force Analysis
  • 5.7. Supply Chain Analysis
  • 5.8. Patent Analysis
  • 5.9. SWOT Analysis
  • 5.10. Unmet Needs and Gaps
  • 5.11. Recommended Strategies for Market Entry and Expansion
  • 5.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 5.13. Pricing Analysis and Price Dynamics
  • 5.14. Key Opinion Leaders

6. By Type

  • 6.1. Introduction
    • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Type
    • 6.1.2. Market Attractiveness Index, By Type
  • 6.2. Screening Mammography*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Diagnostic Mammography
  • 6.4. Breast Tomosynthesis
  • 6.5. Breast Ultrasound
  • 6.6. Breast MRIs

7. By Technology

  • 7.1. Introduction
    • 7.1.1. Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 7.1.2. Market Attractiveness Index, By Technology
  • 7.2. Computed Tomography (CT) Scan*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Magnetic Resonance Imaging (MRI) Scan
  • 7.4. Ultrasound
  • 7.5. Positron Emission Tomography (PET) Scan
  • 7.6. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Breast Disease*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Breast Cancers
  • 8.4. Benign Tumors
  • 8.5. Cysts
  • 8.6. Others

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Diagnostic Centers
  • 9.4. Research Institutes
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.5.1. U.S.
      • 10.2.5.2. Canada
      • 10.2.5.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.5.1. Germany
      • 10.3.5.2. U.K.
      • 10.3.5.3. France
      • 10.3.5.4. Spain
      • 10.3.5.5. Italy
      • 10.3.5.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.5.1. Brazil
      • 10.4.5.2. Argentina
      • 10.4.5.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.5.1. China
      • 10.5.5.2. India
      • 10.5.5.3. Japan
      • 10.5.5.4. South Korea
      • 10.5.5.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

Key Market Players

  • 12.1. GE HealthCare*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio
      • 12.1.2.1. Product Description
      • 12.1.2.2. Product Key Performance Indicators (KPIs)
      • 12.1.2.3. Historic and Forecasted Product Sales
      • 12.1.2.4. Product Sales Volume
    • 12.1.3. Financial Overview
      • 12.1.3.1. Company Revenue's
      • 12.1.3.2. Geographical Revenue Shares
      • 12.1.3.3. Revenue Forecasts
    • 12.1.4. Key Developments
      • 12.1.4.1. Mergers & Acquisitions
      • 12.1.4.2. Key Product Development Activities
      • 12.1.4.3. Regulatory Approvals etc.
    • 12.1.5. SWOT Analysis
  • 12.2. Koning Health
  • 12.3. FUJIFILM Holdings Corporation
  • 12.4. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • 12.5. Hologic, Inc.
  • 12.6. Siemens Healthineers AG
  • 12.7. Agfa-Gevaert Group.
  • 12.8. Koninklijke Philips N.V.
  • 12.9. Planmed Oy
  • 12.10. Seno Medical
  • Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us